rs8192625 were also selected ( Table 1 ). The average genotyping success rates were 99.80 and 98.75% for pyrosequencing (two SNPs) and for TaqMan assays (28 SNPs), respectively. TDT tests using ASPEX 2.5/ sib_tdt (http://aspex.sourceforge.net/) detected four SNPs, including rs9389008, rs4628126, rs1569651 and rs9321360 nominally associated with BD (P < 0.05, Table 1 ). Haplotype blocks were identified by Haploview using the solid spine of LD (Supplementary Figure S1 ) and then analyzed for association by PDTPHASE. 11 One distal haplotype in the TAAR4 gene (named Hap1 here, which includes rs9389008, rs4628126, rs4320395 and rs12189813) showed nominal association with BD (P = 0.0063), with false discovery rate 12 q = 0.071. We then genotyped 12 SNPs in a second sample set including CHIP and NIMH wave 3-4 samples. SNP rs8192624 showed nominally significant association (P = 0.022) in the second set of samples (Table 1) , as well as in the combined samples (P = 0.0048). SNPs rs8192625 and rs4628126 showed P not greater than 0.05 only in combined data analysis ( Table 1) . The haplotype Hap1 in this region showed similar results (P = 0.13 in the second set sample; P = 0.015 in combined data).
The major allele (G) of SNP rs8192624 and rs8192625 in TAAR6 gene was reported to be associated with BD or SZ. 4, 5 Here, we observed nominally significant association between minor allele (A) and BD. The reported allele frequency 4 is similar to that observed in this study. This alleviated our concern for allele call errors as a cause of the discrepant results.
TAAR6 is in a region where most markers are not in LD with each other. We resequenced a 1 kb exonic fragment and 1 kb of putative promoter of TAAR6 in 189 unrelated BD patients from NIMH BD Genetics Initiative and 188 age-and gender-matched mentally healthy unrelated controls from the NIMH Schizophrenia Genetics Initiative collection. Controls were defined as those who did not meet criteria for BD, schizoaffective disorder or SZ. In addition, our selected controls did not meet criteria for panic or recurrent depression that could be met by the diagnostic interview used for that collection.
Twenty-four variants, including eight common variants (MAF > 0.05), were identified from the resequencing. Fifteen of these variants were novel. Eleven variants were in a coding region with one synonymous and 10 nonsynonymous mutations (Supplementary Table S2 ). We looked for a potential rare variant association, as implied in other studies. 13 One common synonymous variant (P26P) was detected in both cases and controls. Four missense mutations appeared uniquely in cases and one missense mutation appeared only in controls. However, no significant difference of distribution or amount of coding mutations was found between the BD and control samples. All singletons identified in patients were inherited from parents, as found by additional sequencing, and some from psychiatrically unaffected parents.
The resequencing data revealed very low LD among most variants in the TAAR6 gene region (data not shown). It is consistent with the rough map from the HapMap project. This also suggests that a true association, if any, in this region may only be detected by testing the causal variant directly.
In conclusion, the present study did not support strong association of either common or rare variants in the TAAR6 gene with BD susceptibility. SNPs rs8192624 and rs8192625 in TAAR6 and a haplotype in TAAR4 gene region remain interesting for possible minor contribution to disease susceptibility. Other candidate genes in this region should be further investigated.
C Liu, J Shi, JA Badner, H Zou, Y Qian and ES Gershon Department of Psychiatry, The University of Chicago, Chicago, IL, USA E-mail: cliu@yoda.bsd.uchicago.edu (MDD). The neurotrophic hypothesis of depression suggests that stress increases the susceptibility to depressive illness via increased hypothalamic-pituitary-adrenal axis activation, in turn decreasing neurotrophic factors that are required for hippocampal neuronal survival and function. 1 Postmortem studies have investigated neurotrophic factors in suicide patients revealing decreased brain-derived neurotrophic factor (BDNF) in the prefrontal cortex and hippocampus 2 and leptin in the hypothalamus. 3 In suicidal patients, BDNF and neurotrophin-4 levels were reduced in cerebrospinal fluid. 4 Recently, low peripheral plasma BDNF concentrations were shown to be associated with suicide behaviour in patients with MDD. 5 Studies utilizing peripheral indices of brain-derived products present methodological complications in that many neurotransmitters and neuromodulators are released from sites other than the brain. 6 Indeed, in humans, BDNF has been identified in platelets 7 and endothelial cells, 8 rendering it difficult to extrapolate directly peripheral BDNF levels to activity in the brain. To circumvent this issue, we used direct internal jugular vein blood sampling methodology 6 to examine the relationship between brain BDNF production and suicide risk in unmedicated patients with MDD. Nineteen subjects (8 men/11 women, aged 4673 years, BMI 2671) meeting DSM-IV diagnostic criteria for MDD were recruited from the community via media advertisement. Patients were either newly diagnosed or with a past history of MDD who had suffered a recent relapse and were on no antidepressant medication or therapy. All subjects were screened for underlying physical illness. Exclusion criteria included comorbid medical conditions such as pre-existing heart disease, diabetes, medicated hypertension, epilepsy, alcohol/drug dependence, infectious blood diseases, comorbid psychotic disorders, eating disorders, mental retardation, dementia (MMSE < 23) and personality disorders. All patients had a psychiatric interview and were evaluated using the full Mini International Neuropsychiatric Interview (MINI). Hamilton depression rating scale (Ham D; 17 items) was used to monitor depression severity. Eligibility for entry were determined by Ham D > 18, major depression diagnosis on MINI and by patients being judged to have a significant major depression as the primary illness at psychiatric interview. Clinician- rated suicide risk was assessed using the suicidality score on the MINI. This comprises thoughts about planning and previous attempts, gaining a score of current suicide risk. Low risk was classified as 1-5 points; medium as 6-9 points; and high as over 10 points. Ethics approval was obtained from the Alfred Hospital Human Research Ethics Committee, and written informed consent was obtained from each participant before the study. Following completion of the study, patients were referred to a psychiatrist for clinical management.
Internal jugular vein and brachial artery blood samples were obtained simultaneously using percutaneously placed catheters as reported previously. 6 The catheter tip was positioned above the jaw in the internal jugular vein to exclude venous drainage from the face. The veno-arterial BDNF plasma concentration gradient was used as an index of brain BDNF production. Plasma BDNF levels were determined using a sandwich Enzyme-Linked Immunosorbent Assay (Promega, Madison, WI, USA). The intra-assay variation of the assay was 3.7%. Data are expressed as mean7s.e.m., or median (25-75 percentile) if data were not normally distributed. Differences between arterial and internal jugular BDNF plasma concentration were assessed using paired Student's t-test, while relationship between brain BDNF production and suicide risk was assessed using the Spearman rank order correlation. P < 0.05 was considered statistically significant.
Patients' Ham D scores were 2571 (range: 20-34). Patients had experienced 2.8 previous episodes of depression, on average, while this was the first episode for two subjects. The current depressive episode was less than 3 months for three participants, while 10 participants had been currently depressed for more than 1 year. In all patients combined, the arterial plasma BDNF concentration was 238871864 pg/ml (Table 1) . Arterial BDNF levels bore no association to the level of depression or to the risk of suicide. Internal jugular vein sampling was unsuccessful in three patients. Indicative of brain production of BDNF, positive internal jugular venoarterial BDNF concentration gradients were evident, with the internal jugular BDNF plasma concentration being 1277109% higher than the corresponding arterial concentration (P = 0.04, Table 1 ). Given that BDNF is stored and released from platelets, 9 the elevated internal jugular venous BDNF plasma concentration that we find could occur as a result of disruption of platelets in transit through the sampling catheter. While possible, this is unlikely to account for the difference in values observed in patients at differing suicide risk given that all patients underwent the same blood taking procedure.
Mean suicide risk on the MINI was 571 (range: 0-19; Table 1 ). Eleven patients had low suicide risk and eight patients were considered moderate to high risk. The veno-arterial BDNF concentration gradient was significantly reduced in patients at medium to high suicide risk (0 (0-7) vs 34 (21-437)%, median (25-75 percentile), P = 0.015, Table 1 ). Moreover, a significant negative correlation existed between suicide risk and the internal jugular venous veno-arterial BDNF concentration gradient (r = À0.721, P = 0.001; venoarterial BDNF = 329-(27 Â suicide risk)). The internal jugular BDNF concentration gradient was not significantly associated with severity of depression.
This report, documenting an association between internal jugular venous BDNF overflow and suicide risk, coupled with our previous study demonstrating reduced subcortical monoamine turnover and diminished brain glucose utilization in patients with treatment refractory depression, 10 provide compelling evidence in support of the neurotrophic hypothesis of depression. Given the previous findings of low BDNF levels in the hippocampus of suicide victims,
